The modulated pathways in which the upregulated genes participated in CCC I patients versus HD were the same three immunological pathways (IL-10 signaling [FDR = 5.83e−17]; IL-4 and IL-13 signaling [2.75e−13]; and IL-18 signaling [FDR = 8.75e−13]) than those downregulated in treated versus untreated CCC I patients (Supplementary Figure S2). This evidence concerns the gene IL13 and Huntington disease.